+Compare
SAVA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
894.09M

SAVA Price Prediction, Cassava Sciences AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for SAVA with price predictions
07:00 PM EST Nov 27, 2023

SAVA's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for SAVA moved out of overbought territory on November 03, 2023. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 instances where the indicator moved out of the overbought zone. In of the 34 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where SAVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SAVA turned negative on November 22, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SAVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on SAVA as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

SAVA moved above its 50-day moving average on October 25, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SAVA crossed bullishly above the 50-day moving average on November 02, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SAVA advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 153 cases where SAVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.764) is normal, around the industry mean (20.498). P/E Ratio (0.000) is within average values for comparable stocks, (137.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.811). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.636).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SAVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SAVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I. Advisor
published Earnings

SAVA is expected to report earnings to rise 46.72% to -89 cents per share on March 27

Cassava Sciences SAVA Stock Earnings Reports
Q4'23
Est.
$-0.89
Q3'23
Beat
by $0.16
Q2'23
Missed
by $0.04
Q1'23
Missed
by $0.02
Q4'22
Beat
by $0.09
The last earnings report on November 07 showed earnings per share of -61 cents, beating the estimate of -77 cents. With 87.40K shares outstanding, the current market capitalization sits at 894.09M.
A.I.Advisor
published Dividends

SAVA paid dividends on December 24, 2012

Cassava Sciences SAVA Stock Dividends
А dividend of $0.75 per share was paid with a record date of December 24, 2012, and an ex-dividend date of December 13, 2012. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was 37%, and the average quarterly price growth was 8%. AWKNF experienced the highest price growth at 165%, while AXLA experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -21% and the average quarterly volume growth was 24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
6801 N. Capital of Texas Highway
Phone
+1 512 501-2444
Employees
26
Web
https://www.cassavasciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CIHIX10.220.05
+0.49%
Cullen International High Dividend I
PAITX18.300.03
+0.16%
T. Rowe Price International Stock Adv
BIEAX19.00N/A
N/A
Brandes International Equity A
AVLIX7.81N/A
N/A
American Century Value I
GUMAX27.78-0.02
-0.07%
Guggenheim Market Neutral Rel Est A

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
-2.12%
CRSP - SAVA
35%
Loosely correlated
-1.33%
VCYT - SAVA
35%
Loosely correlated
-2.24%
ADPT - SAVA
31%
Poorly correlated
+0.92%
NVAX - SAVA
31%
Poorly correlated
+4.95%
AVXL - SAVA
31%
Poorly correlated
+6.60%
More